7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,299.80

-252.55

-0.33%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

Elutia Inc. (ELUT)

0.8371 +0.0235 (+2.89%)

At close: October 30 at 4:00:01 PM EDT

Loading Chart for ELUT

Chart Range Bar

Interval:

In partnership with ChartIQ

Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

Elutia (ELUT) Q2 2026 Earnings Call Transcript

Elutia (ELUT) Q2 2026 Earnings Call Transcript

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ...

Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ...

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio

Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Mobilize your Website

View Site in Mobile | Classic

Share by: